Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis.’ The study aims to evaluate the safety and tolerability of the drug Apremilast in children with mild to moderate plaque psoriasis, marking a significant step in expanding treatment options for this demographic.
The intervention being tested is Apremilast, an oral tablet administered twice daily based on the participant’s body weight. This drug is intended to manage symptoms of plaque psoriasis in pediatric patients.
The study follows an interventional design with a single-group model, meaning all participants receive the treatment. There is no masking involved, and the primary purpose is treatment-focused, ensuring a straightforward approach to assessing the drug’s safety.
The study began on October 24, 2023, with the primary completion and estimated study completion dates yet to be announced. The last update was submitted on August 13, 2025, indicating ongoing progress.
This update could positively influence Amgen’s stock performance by showcasing the company’s commitment to expanding its product offerings in the pediatric market. It may also affect investor sentiment positively, as successful trials could lead to new revenue streams. Competitors in the pediatric psoriasis treatment market will likely monitor these developments closely.
The study is currently recruiting, with further details available on the ClinicalTrials portal.